Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report
Saved in:
| Published in: | OncoTargets and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301678680637444 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | OncoTargets and Therapy |
| description | |
| discipline_display | Oncology |
| discipline_facet | Oncology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:61287 |
| institution | FRELIP |
| journal_source_facet | OncoTargets and Therapy |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report Oncology General Oncology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Oncology General Oncology Oncology General Oncology |
| subject_facet | Oncology General Oncology |
| title | Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report |
| title_auth | Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report |
| title_full | Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report |
| title_fullStr | Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report |
| title_full_unstemmed | Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report |
| title_short | Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report |
| title_sort | acquired braf-agk fusion following osimertinib plus savolitinib in egfr-mutated met-amplified non-small-cell lung cancer: durable response to gefitinib and trametinib in a case report |
| topic | Oncology General Oncology |
| url | https://www.dovepress.com/acquired-braf-agk-fusion-following-osimertinib-plus-savolitinib-in-egf-peer-reviewed-fulltext-article-OTT |